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Treatment with UDCA together with dexamethasone leads to upregulated 


































The combination of UDCA and dexamethasone increases the AE2 anion 














The combination of UDCA and dexamethasone upregulates AE2 
alternative expression in NHCs. The mRNA levels for AE2b1, 
AE2b2, and AE2a isoforms were determined by real-time PCR in 
cultured NHCs treated for 24 or 72 hours with either dexametha-
sone (DEX) and/or UDCA, GUDCA, TUDCA, CA, or CDCA (100 
μM each) or with just vehicle. Values (normalized for GAPDH 
mRNA) are given as fold expression relative to values in the 
respective controls with just vehicle. Data are mean ± SD; n = 6 
(except for GUDCA, TUDCA, CA, and CDCA — with and without 
DEX — for which n = 3 each). *P < 0.05, **P < 0.01, ***P < 0.001 
versus vehicle control.
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in  these  cells.  To  assess  this  possibility, we  performed AE2-
knockdown experiments in both human liver cell types through 
cotransfection  with  silencing  pSUPER  plasmid  constructs 
— either shRNA-1 or shRNA-2 (described in ref. 21) — together 

































Combined treatment with UDCA and dexamethasone enhanc-































UDCA together with dexamethasone upregulates AE2 alter-
native expression in hepatocyte lineage PLC/PRF/5 cells. 
The mRNA levels for AE2b1, AE2b2, and AE2a isoforms 
were determined by real-time PCR in PLC/PRF/5 cells 
treated for 24 or 72 hours with either dexamethasone and/
or UDCA, GUDCA, TUDCA, CA, or CDCA (100 μM each) 
or with just vehicle. Values (normalized for GAPDH mRNA) 
are given as fold expression relative to values in the respec-
tive controls with just vehicle. Data are mean ± SD; n = 6 
(except for GUDCA, TUDCA, CA, and CDCA — with and 
without DEX — for which n = 3 each). *P < 0.05, **P < 0.01, 
***P < 0.001 versus vehicle control.
research article






Role of specific regulatory elements in the stimulatory effect of UDCA 









































into  a  complete  GRE  site. 


































The combination of UDCA and dexamethasone increases AE activities in hepatobiliary cells. Cl–/HCO3– AE 
activity was determined by microfluorimetry in NHCs (A) and PLC/PRF/5 cells (B) following treatments for 
24 hours with either dexamethasone and/or UDCA, GUDCA, TUDCA, CA, or CDCA (100 μM each) or with 
just vehicle. Treated cells were analyzed for AE activities, both baseline (left) and in the presence of a cAMP-
stimulation mixture (right). The AE activity was estimated as the rate of pHi recovery from propionate-induced 
intracellular alkalinization. Rates of pHi change were measured as δpHi/δt from the tangent to the experi-
mental plot; transmembrane acid fluxes (or equivalent transmembrane base fluxes, JOH– [mmol/l/min]) were 
calculated as βtot × δpHi/δt, where βtot is the total intracellular buffering power in the presence of CO2/HCO3–. 
Data are mean ± SD; n = 9 each. *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle control.
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Role of HNF1α in the stimulation of AE2 alternate promoter by UDCA 


































Involvement of p300 in the UDCA plus dexamethasone–dependent inter-








AE2 silencing experiments indicate that AE activities displayed by hep-
atobiliary cells are mediated by AE2. (A) AE2 silencing was assessed 
in PLC/PRF/5 cells by quantifying the mRNA levels for AE2a, AE2b1, 
and AE2b2 isoforms 3 days after transient transfection with pSUPER 
plasmid constructs (either shRNA-1 silencing construct, shRNA-2 
silencing construct, or pSUPER empty vector as control, each together 
with GFP expression vector). AE2 mRNA values were normalized with 
GAPDH mRNA levels and corrected for the transfection efficiency with 
GFP mRNA levels. Values are given as percentage of mRNA levels 
relative to the control. (B) Baseline and cAMP-stimulated AE activities 
were determined by microfluorimetry in PLC/PRF/5 cells transfected 
with shRNA-1 silencing construct (together with GFP expression vec-
tor) and treated for 24 hours either with UDCA plus dexamethasone or 
with just vehicle. (C) Baseline and cAMP-stimulated AE activities were 
determined by microfluorimetry in NHCs transfected with shRNA-1 
silencing construct (together with GFP expression vector) and treated 
for 24 hours either with UDCA plus dexamethasone or with just vehi-
cle. In both B and C, cotransfected cells could be differentiated from 
nontransfected cells in the same field of the microscope for their appro-
priate analysis. Data are mean ± SD; n = 6 each.
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Luciferase constructs with 
sequences of the human AE2 
alternate promoter. The upper 
diagram shows AE2 alternate 
promoter regions from the dis-
tal part of intron 1 to the end of 
exon 1b1. Negative numbers 
followed by b1 or b2 indicate 
nucleotide positions upstream 
to respective +1 positions (i.e., 
A in ATG start codons) in exons 
1b1 or 1b2, respectively. HNF1 
site (gray arrow) and 2 GREcore 
motifs (open rhombuses) are also 
shown. Luciferase constructs II-b2 
and I-b1 contain partial sequences 
of AE2 alternate overlapping pro-
moter. Construct I-b1[HNF1]mut 
has the HNF1 site mutated (indi-
cated by X instead of gray arrow). 
In construct I-b1GRETat, 6 bases 
(underlined) had been replaced 
to form the complete GRE site of 
the rat Tat promoter. I-b1[–358b1/ 
–239b1]Δ is a construct internally 
deleted for the –358b1/–239b1 
region and thus lacking the 2 
GREcore motifs. Constructs 
I-b1[–327b1]mut, I-b1[–245b1]mut, 
and I-b1[–327b1&–245b1]mut have 
abrogating mutations in GREcore 
motifs (indicated by underlined 
nucleotides above wild-type motif 
sequences).
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In vitro, the combination of UDCA and dexamethasone 
upregulates the transcriptional activity of AE2 alternate 
promoter regions in transfected PLC/PRF/5 cells. (A) 
Diagram of AE2 promoter regions (gray arrows indicate 
the HNF1 site; open rhombuses represent GREcore 
motifs) and luciferase constructs II-b2 and I-b1, with 
luciferase activities of PLC/PRF/5 cells transiently trans-
fected (0.1 μg of respective construct) and treated for 
24 hours either with UDCA plus dexamethasone or with 
just vehicle. (B) Dose-dependent luciferase activities of 
PLC/PRF/5 cells transiently transfected with luciferase 
construct I-b1 (0.1 μg) and treated for 24 hours with dif-
ferent concentrations of UDCA and/or dexamethasone. 
Luciferase activities (normalized with Renilla activi-
ties) are given as fold activity relative to the activity of 
construct I-b1 in the absence of UDCA and DEX. Data 
are mean ± SD; n = 9 each. *P < 0.05, **P < 0.01, 
***P < 0.001 versus vehicle control.
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In vivo, the combination of UDCA and dexamethasone upregulates 
the transcriptional activity of AE2 alternate promoter sequences in 
injected BALB/c mice. (A) Seven days after their hydrodynamic injec-
tion with luciferase construct I-b1 (30 μg), BALB/c mice were treated 
with UDCA, dexamethasone, UDCA plus dexamethasone, or just 
vehicle. After 1 hour, luminescence in the abdominal area was deter-
mined by mouse bioluminescence as described in Methods. Typical 
mouse images corresponding to each treatment are shown. Normal-
izing values (n.v.) are quotients obtained for each animal after DNA 
quantifications (through real-time PCR) for the luciferase gene (as 
transfected gene) and the albumin gene (as endogenous gene) in the 
liver. (B) Abdominal luminescence in injected animals after the differ-
ent treatments. Luminescence units were corrected with normalizing 
values. Normalized values are given as fold corrected luminescence 
units relative to those in nontreated mice. Data are mean ± SD; n = 4 
each. *P < 0.05 versus vehicle control.
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In vitro and in vivo role of GREcore motifs for the effects of UDCA and dexamethasone on AE2 alternate promoter. (A) Luciferase activity of 
PLC/PRF/5 cells transiently transfected either with wild-type construct I-b1 or with deleted construct I-b1[–358b1/–239b1]Δ (cf. Figure 5) and 
treated for 24 hours with UDCA and/or dexamethasone. (B) Luciferase activity in PLC/PRF/5 cells transfected either with construct I-b1 or with 
constructs mutated at the GREcore motif(s) (cf. Figure 5) and treated for 24 hours with UDCA and/or DEX. In both A and B, luciferase activi-
ties (normalized with Renilla activity) are given as fold activity relative to the activity in cells transfected with construct I-b1 in the absence of 
UDCA and DEX; data are mean ± SD; n = 9 each. (C) Representative images of abdominal luminescence in BALB/c mice injected with 30 μg of 
luciferase constructs mutated at the GREcore motif(s) (cf. Figure 5) and treated with UDCA, DEX, UDCA plus dexamethasone, or just vehicle, 
as described in Methods. Normalizing values are quotients obtained for each animal after DNA quantifications (through real-time PCR) for the 
luciferase gene (as transfected gene) and the albumin gene (as endogenous gene) in the liver. (D) Values of abdominal luminescence in mice 
injected and treated as in C. Luminescence units from each animal had been corrected with corresponding normalizing values and are shown 
as fold corrected luminescence units relative to those in mice injected with construct I-b1 and with just vehicle (i.e., with no UDCA or DEX admin-
istration). Data are mean ± SD; n = 4 each.
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Mutations immediately upstream from the GREcore –327b1 site leading 
to a complete GRE site resulted in full responsiveness of AE2 alternate 
promoter to either UDCA or dexamethasone alone. Luciferase activi-
ties of PLC/PRF/5 cells transiently transfected with construct I-b1 or 
I-b1GRETat — the latter having the complete sequence of the GRE site in 
the rat Tat promoter, as depicted in Figure 5 — and treated for 24 hours 
with UDCA and/or dexamethasone. Values of luciferase activity (normal-
ized with Renilla values) are given as fold activity relative to the activity 
in cells transfected with construct I-b1 in the absence of UDCA and DEX 
(indicated by a vertical arrow). Data are mean ± SD; n = 9 each.
Figure 10
Interaction of GR with the GREcore site at position –327b1 in the AE2 
alternate promoter depends on simultaneous treatment of PLC/PRF/5 
cells with UDCA and dexamethasone. (A) ChIP assays against human 
GR from extracts of PLC/PRF/5 cells treated for 24 hours with UDCA, 
dexamethasone, UDCA plus dexamethasone, or just vehicle. In the 
upper diagram, the gray bar refers to the amplicon –391b1/–239b1 
(which includes GREcore –327b1) expected in the PCR amplifications 
shown below. The following templates were used: DNA negative (just 
water as negative control), DNA positive (human genomic DNA as 
positive PCR control), input (start material), mock (no antibody), IgG 
(rabbit total IgG) — the latter 2 as negative immunoprecipitation con-
trols — and GR immunoprecipitate. Protein A/G–agarose–unbound 
DNA fractions were also used as control templates. (B) Immunoblots 
of cytosolic and nuclear extracts from PLC/PRF/5 cells treated as 
described above, using an antibody against human GR. Control of 
loaded proteins shown below resulted from ponceau staining of the 
transferred membrane. (C) In the upper diagram, the gray bar refers 
to the amplicon –827b1/–534b1 (which includes the HNF1 element). 
Amplifications shown below were obtained with the same templates 
as in A. In upper diagrams of A and C, gray arrows indicate the HNF1 
site; open rhombuses represent GREcore motifs.
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Role of the HNF1α and its interaction with the HNF1 element for the 
effects on AE2 alternate promoter following simultaneous treatment of 
PLC/PRF/5 cells with UDCA and dexamethasone. (A) Luciferase activi-
ties of PLC/PRF/5 cells transiently transfected with wild-type construct 
I-b1 or with HNF1-mutated construct I-b1[HNF1]mut and treated for 24 
hours with UDCA and/or dexamethasone. Values of luciferase activity 
(normalized with Renilla values) are given as fold activity relative to the 
activity in cells transfected with construct I-b1 treated with just vehicle 
(i.e., in the absence of UDCA and DEX). Data are mean ± SD; n = 9 
each. (B) ChIP assays with HNF1α immunoprecipitates from extracts 
of PLC/PRF/5 cells treated as described in Figure 10, in which the 
region that includes the HNF1 element was amplified (amplicon –827b1/ 
–534b1; see the gray bar in the upper diagram). Positive and negative 
controls were equivalent to those in Figure 10A, but IgG for the negative 
immunoprecipitation control was goat total IgG. (C) ChIP assays with 
HNF1α immunoprecipitates in which the region that includes GREcore 
–327b1 (amplicon –391b1/–239b1 indicated by a gray bar in the upper 
diagram) was amplified using the same templates as in B. In upper dia-
grams of B and C, gray arrows indicate the HNF1 site; open rhombuses 
represent GREcore motifs.
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The coregulatory factor p300 may function as a scaffold protein for 
the interaction of GR and HNF1α on the AE2 alternate promoter in 
PLC/PRF/5 cells following simultaneous treatment with UDCA and 
dexamethasone. (A) ChIP assays with p300 immunoprecipitates from 
extracts of PLC/PRF/5 cells treated as described in Figure 10, in which 
the region that includes GREcore –327b1 (amplicon –391b1/–239b1) 
was amplified. Positive and negative controls were equivalent to those 
in Figure 10A, but IgG for the negative immunoprecipitation control 
was mouse total IgG. (B) ChIP assays with p300 immunoprecipitates 
in which the region that includes the HNF1 element (amplicon –827b1/ 
–534b1) was amplified using the same templates as in A. (C) ChIP 
assays with p300 immunoprecipitates in which the intervening region 
between HNF1 and GREcore –327b1 elements (amplicon –571b1/ 
–359b1) was amplified using the same templates as in A. Gray bars in 
the upper diagrams refer to the corresponding amplicons; gray arrows 
indicate the HNF1 site; open rhombuses represent GREcore motifs.
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with  lysis  buffer  (without NP-40)  and  dissolved  in  20 mM HEPES 
pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 10% glyc-
erol, and CPI, through vigorous shaking (20 minutes). After 10 minutes 



















Western blot analysis using whole-cell extracts from NHCs and PLC/
PRF/5 cells. Total lysate from normal human liver (NHL) (shown in 
between) was used for a comparison with a normal expression pat-
tern of these proteins in whole liver tissue. Electrophoresed proteins 
were electrotransferred and probed with antibodies against GR, 
HNF1α, and HNF1β. Loading control was carried out with an anti-
body against β-actin.
Figure 14
Non-liver PC3 cells transfected with a luciferase construct with the 
AE2b2/AE2b1 overlapping promoter sequence become responsive to 
the combination of UDCA and dexamethasone when cotransfected with 
expression vectors for either HNF1α or HNF1β. PC3 cells transfected 
with construct I-b1 or HNF1 site mutated construct I-b1[HNF1]mut were 
each cotransfected with either pBJ5-HNF1α, pBJ5-HNF1β, or empty 
pBJ5 expression vectors and then treated for 24 hours with UDCA and 
dexamethasone or with just vehicle. Luciferase activities (normalized 
with Renilla activities) are given as fold activity relative to the activity of 
construct I-b1 in the absence of UDCA and DEX. Data are mean ± SD; 
n = 9 each. *P < 0.001 versus vehicle control.
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–239b1  (which  includes GREcore  site  at  –327b1)  and –827b1/–534b1 
(with the HNF1 element) were obtained by using the following primers: 
forward 5′-ACAGGAGCCTTCCTCACAGA-3′  and reverse 5′-CAGAA-



















































































































sensitivity  of  AE2c1-mediated  anion  exchange 
reveals novel regulatory determinants in the AE2 
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